© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral drug, covalent inhibitor of KRASG12C
effective in KRASG12C-mutated cancer models
SBDD utilizing KRAS proto-oncogene, GTPase
British Journal of Cancer
Astellas Pharma Inc.
3. The Astellas KRASG12C covalent inhibitor, ASP2453, is an oral molecule with activity in preclinical mouse models of KRASG12C-mutated cancer at lower doses than sotorasib (AMG 510). Several KRAS inhibitors have…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.